Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VXA-G1.1-NN Phase 1 Trial in Healthy Volunteers
NCT02868073Phase 1Completed
- Sponsor
- Vaxart, Inc.
- Start
- Jul 2016
- Primary completion
- Oct 2016
- Modality
- Drug Delivery Systems, Vaccines & Immunotherapeutics, Adenoviral Vectors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of VXA-GI.1.NN in norovirus gastroenteritis (3 arms), sponsored by Vaxart, Inc. Primary endpoint: Incidence of Treatment Emergent Solicited and Unsolicited Adverse Events. Started Jul 2016; status: completed.
02
Drugs
VXA-GI.1.NN
03
Conditions
norovirus gastroenteritis
Beyond the preview
Go deeper on NCT02868073.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02868073.